3 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Plexiform Neurofibroma: new trials by email Literature Review of Plexiform Neurofibroma trials Research Report on Plexiform Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-11-04 |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 FCN-159 - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 160 | 2021-03-26 | 2024-11-12 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics - Neurofibromatosis Type I, Plexiform Neurofibroma | Phase 1 | Completed | National Cancer Institute (NCI) | 9 | 2008-07-08 | 2019-12-12 |
Neurofibroma, Plexiform (6) · Neurofibromatosis 1 (5) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Neoplasms (1) · Neuroblastoma (1) · Optic Nerve Glioma (1)
Neoplasms by Histologic Type (6) · Neoplasms, Nerve Tissue (6) · Nerve Sheath Neoplasms (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Neurofibroma (6) · Neuromuscular Diseases (6) · Peripheral Nervous System Diseases (6) · Peripheral Nervous System Neoplasms (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Neoplasms (5) · Neoplastic Syndromes, Hereditary (5) · Neurocutaneous Syndromes (5)
AZD 6244 (2) · Pharmacokinetics (1) · Sorafenib (1) · cabozantinib (1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · Girish Dhall, MD (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (4) · China (2) · Spain (1) · United Kingdom (1)
Brigitte C Widemann, M.D. (1) · Darren Hargrave, MB Bch (1) · Girish Dhall, MD (1) · Sameer Farouk Sait, MD (1)